High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: A randomized, multicenter trial

Nelly Mauras, Kenneth M. Attie, Edward O. Reiter, Paul Saenger, Joyce Baptista, Gilbert P. August, Jennifer J. Bell, Thomas P. Foley, Ronald W. Gotlin, Madeleine D. Harbison, Raymond L. Hintz, Nancy J. Hopwood, Margaret H. MacGillivray, Nelly Mauras, Wayne V. Moore, Thomas Moshang, Katrina L. Parker, Leslie P. Plotnick, Edward O. Reiter, Alan D. RogolWilliam E. Russell, Paul Saenger, Dennis M. Styne, Thomas A. Wilson, David T. Wyatt

Research output: Contribution to journalArticle


GH production rates markedly increase during human puberty, mostly as an amplitude-modulated phenomenon. However, GH-deficient children have been dosed on a standard per kg BW basis similar to prepubertal children. This randomized study was designed to compare the efficacy and safety of standard recombinant human GH (rhGH) therapy (group I, 0.3 mg/kg·week) vs. high dose therapy (group II, 0.7 mg/kg·week) in GH-deficient adolescents previously treated with rhGH for at least 6 months. Ninety-seven children with documented evidence of GH deficiency (peak GH in response to stimuli,

Original languageEnglish (US)
Pages (from-to)3653-3660
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Issue number10
Publication statusPublished - 2000


ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this